Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114825 | 1.00 | TSHR (0.43) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL2566312 | 0.83 | TSHR (0.48) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL2566313 | 0.83 | TSHR (0.48) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL8498824 | 0.83 | TSHR (0.48) | TSHRFAAHTRPV1ADH1BADH1C | |
| SCHEMBL1114641 | 0.82 | PTPN1 (0.40) | TSHRCA2PTPN1 | |
| SCHEMBL1114632 | 0.82 | PTPN1 (0.40) | TSHRCA2PTPN1 | |
| SCHEMBL1978036 | 0.79 | FAAH (0.38) | FAAH | |
| SCHEMBL1114915 | 0.78 | — | — | |
| SCHEMBL1114904 | 0.78 | TP53 (0.34) | — | |
| SCHEMBL13737406 | 0.78 | TSHR (0.53) | TSHRFAAHTRPV1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889894-B2 | Compounds for use in therapy | BANGOR UNIVERSITY (GB) | 2014-11-18 | — | — | US | disclosed |
| US-8728515-B2 | Adjuvants for use in vaccination | BANGOR UNIVERSITY (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2620158-A1 | Adjuvants for use in vaccination | Bangor University (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20110150981-A1 | Compounds for Use in Therapy | BANGOR UNIVERSITY (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20110142916-A1 | Adjuvants for Use in Vaccination | BANGOR UNIVERSITY (GB) | 2011-06-16 | — | — | US | disclosed |
| EP-2278995-A2 | COMPOUNDS FOR USE IN THERAPY | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2278996-A1 | ADJUVANTS FOR USE IN VACCINATION | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009130506-A2 | COMPOUNDS FOR USE IN THERAPY | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130508-A1 | ADJUVANTS FOR USE IN VACCINATION | BANGOR UNIVERSITY (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142916-A1 | Adjuvants for Use in Vaccination | NR1H3, NR1H2, INTS6 | TSHR 46/4885FAAH 1641/4885TRPV1 3262/4885 |
| US-20110150981-A1 | Compounds for Use in Therapy | CD4, MSR1, TST | TSHR 38/4885FAAH 1400/4885TRPV1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.